title: [Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma].
abstract: BACKGROUND
  The most common types of non-Hodgkin lymphoma (NHL) are diffuse large B cell (DLBCL) and follicular (FL).
  
  
  OBJECTIVE
  To analyze the benefit of Rituxi-mab in overall survival (OS) of patients with NHL.
  
  
  METHODS
  Review of medical record of 230 adult patients with a first episode of NHL admitted between 2002 and 2011. We included 67 patients with DLBCL and 36 patients with FL.
  
  
  RESULTS
  The overall response (OR) was 64% with 39% complete remissions (CR) in DLBCL treated with CHOP-like and 100% with 89% CR with R-CHOP. The median OS with CHOP-like was 21 months versus not attained R-CHOP (p = 0.016). There was a statistically significant difference in median event-free survival (EvFS) in favor of R-CHOP: not attained versus 8.3 months for CHOP-like (log rank (p = 0.002)). In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. With CHOP-like the OR was 59%> with 18% CR. The OS at 24 and 36 months in patients treated with R-CHOP or R-CHOP-like was 83 and 65%. The figures for patients treated with CHOP-like were 80 and 66%> respectively. The progression free survival (PFS) was 21 months with CHOP-like versus not attained with R-QT (p = 0,043).
  
  
  CONCLUSIONS
  When Rituximab was added to CHOP, there was a higher CR, EvFS and OS in DLBCL and higher CR and PFS in FL.
authors.affiliation: Hospital de Clínicas, Montevideo, Uruguay, carolinaoliver@adinet.com.uy.
authors.forename: Carolina
authors.initials: C
authors.lastname: Oliver
authors.affiliation: Hospital de Clínicas, Montevideo, Uruguay, carolinaoliver@adinet.com.uy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Guillermo
authors.affiliation: Hospital de Clínicas, Montevideo, Uruguay, carolinaoliver@adinet.com.uy.
authors.forename: Paula
authors.initials: P
authors.lastname: Martínez
authors.affiliation: Hospital de Clínicas, Montevideo, Uruguay, carolinaoliver@adinet.com.uy.
authors.forename: Lilián
authors.initials: L
authors.lastname: Díaz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone